The clinical features and therapeutic results in patients diagnosed with idiopathic inflammatory myositis: single center experience

Fatih Albayrak; Arif Babayiğit; Neşe Çabuk Çelik; Ali Şahin

Makale detayları

The clinical features and therapeutic results in patients diagnosed with idiopathic inflammatory myositis: single center experience

Yazarlar:

Fatih Albayrak | Arif Babayiğit | Neşe Çabuk Çelik | Ali Şahin

Yayıncı:

Hatay Mustafa Kemal University

Ana Başlıklar:

Internal Diseases

Dergi:

Interdisciplinary Medical Journal Vol.16 Issue 55, pp.109-115

Belge Tipi:

Makale

Yayın Tarihi:

8/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001356118

pISSN:

2980-1915

Anahtar kelimeler:

Özet:

 Objective: This study assessed clinical features, laboratory profiles, and treatment outcomes in idiopathic inflammatory myopathies IIMs patients after six months of immunosuppression. Method: Retrospective analysis occurred at a tertiary rheumatology center. Baseline and six-month post-therapy assessments were conducted on patients diagnosed with polymyositis or dermatomyositis. Records were kept of clinical symptoms, laboratory markers, and muscle strength scores. Results: With a mean age of 4311.1 years and an almost even gender distribution 48.4 female, 31 patients were enrolled. Of these individuals, 87.1 were diagnosed with polymyositis and 12.9 with dermatomyositis. At baseline, the predominant symptom was muscle weakness 77.4, alongside notably high levels of muscle enzymes median creatinine kinase CK: 3340 IUL and inflammatory markers C-reactive protein CRP: 11.4 mgL, erythrocyte sedimentation rate ESR: 39 mmh. Positivity for Jo-1 and Ro52 autoantibodies was found in 16.1 of the cases. Following six months of treatment, there were significant reductions in all laboratory markers p0.001, and all patients exhibited improved muscle strength 55. Conclusion: Patients with IIMs experience significant biochemical and clinical improvement with immunosuppressive therapy. Optimal recovery and long-term muscle function depend on early diagnosis and personalized treatments.

 Objective: This study assessed clinical features, laboratory profiles, and treatment outcomes in idiopathic inflammatory myopathies IIMs patients after six months of immunosuppression. Method: Retrospective analysis occurred at a tertiary rheumatology center. Baseline and six-month post-therapy assessments were conducted on patients diagnosed with polymyositis or dermatomyositis. Records were kept of clinical symptoms, laboratory markers, and muscle strength scores. Results: With a mean age of 4311.1 years and an almost even gender distribution 48.4 female, 31 patients were enrolled. Of these individuals, 87.1 were diagnosed with polymyositis and 12.9 with dermatomyositis. At baseline, the predominant symptom was muscle weakness 77.4, alongside notably high levels of muscle enzymes median creatinine kinase CK: 3340 IUL and inflammatory markers C-reactive protein CRP: 11.4 mgL, erythrocyte sedimentation rate ESR: 39 mmh. Positivity for Jo-1 and Ro52 autoantibodies was found in 16.1 of the cases. Following six months of treatment, there were significant reductions in all laboratory markers p0.001, and all patients exhibited improved muscle strength 55. Conclusion: Patients with IIMs experience significant biochemical and clinical improvement with immunosuppressive therapy. Optimal recovery and long-term muscle function depend on early diagnosis and personalized treatments.

 Objective: This study assessed clinical features, laboratory profiles, and treatment outcomes in idiopathic inflammatory myopathies IIMs patients after six months of immunosuppression. Method: Retrospective analysis occurred at a tertiary rheumatology center. Baseline and six-month post-therapy assessments were conducted on patients diagnosed with polymyositis or dermatomyositis. Records were kept of clinical symptoms, laboratory markers, and muscle strength scores. Results: With a mean age of 4311.1 years and an almost even gender distribution 48.4 female, 31 patients were enrolled. Of these individuals, 87.1 were diagnosed with polymyositis and 12.9 with dermatomyositis. At baseline, the predominant symptom was muscle weakness 77.4, alongside notably high levels of muscle enzymes median creatinine kinase CK: 3340 IUL and inflammatory markers C-reactive protein CRP: 11.4 mgL, erythrocyte sedimentation rate ESR: 39 mmh. Positivity for Jo-1 and Ro52 autoantibodies was found in 16.1 of the cases. Following six months of treatment, there were significant reductions in all laboratory markers p0.001, and all patients exhibited improved muscle strength 55. Conclusion: Patients with IIMs experience significant biochemical and clinical improvement with immunosuppressive therapy. Optimal recovery and long-term muscle function depend on early diagnosis and personalized treatments.

 Objective: This study assessed clinical features, laboratory profiles, and treatment outcomes in idiopathic inflammatory myopathies IIMs patients after six months of immunosuppression. Method: Retrospective analysis occurred at a tertiary rheumatology center. Baseline and six-month post-therapy assessments were conducted on patients diagnosed with polymyositis or dermatomyositis. Records were kept of clinical symptoms, laboratory markers, and muscle strength scores. Results: With a mean age of 4311.1 years and an almost even gender distribution 48.4 female, 31 patients were enrolled. Of these individuals, 87.1 were diagnosed with polymyositis and 12.9 with dermatomyositis. At baseline, the predominant symptom was muscle weakness 77.4, alongside notably high levels of muscle enzymes median creatinine kinase CK: 3340 IUL and inflammatory markers C-reactive protein CRP: 11.4 mgL, erythrocyte sedimentation rate ESR: 39 mmh. Positivity for Jo-1 and Ro52 autoantibodies was found in 16.1 of the cases. Following six months of treatment, there were significant reductions in all laboratory markers p0.001, and all patients exhibited improved muscle strength 55. Conclusion: Patients with IIMs experience significant biochemical and clinical improvement with immunosuppressive therapy. Optimal recovery and long-term muscle function depend on early diagnosis and personalized treatments.

Makale detayları

The clinical features and therapeutic results in patients diagnosed with idiopathic inflammatory myositis: single center experience

Yazarlar:

Fatih Albayrak | Arif Babayiğit | Neşe Çabuk Çelik | Ali Şahin

Yayıncı:

Hatay Mustafa Kemal University

Ana Başlıklar:

Internal Diseases

Dergi:

Interdisciplinary Medical Journal Vol.16 Issue 55, pp.109-115

Belge Tipi:

Makale

Yayın Tarihi:

8/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001356118

pISSN:

2980-1915

Dermatomyositis

idiopathic inflammatory myopathies

immunosuppressive therapy

Sayı

Makale detayları

The clinical features and therapeutic results in patients diagnosed with idiopathic inflammatory myositis: single center experience

Yazarlar: Fatih Albayrak | Arif Babayiğit | Neşe Çabuk Çelik | Ali Şahin

Yayıncı: Hatay Mustafa Kemal University

Ana Başlıklar: Internal Diseases

Dergi: Interdisciplinary Medical Journal Vol.16 Issue 55, pp.109-115

Belge Tipi: Makale

Yayın Tarihi: 8/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001356118

pISSN: 2980-1915

Dermatomyositis

idiopathic inflammatory myopathies

immunosuppressive therapy

Sayı

Yazarlar:

Fatih Albayrak | Arif Babayiğit | Neşe Çabuk Çelik | Ali Şahin

Yayıncı:

Hatay Mustafa Kemal University

Ana Başlıklar:

Internal Diseases

Dergi:

Interdisciplinary Medical Journal Vol.16 Issue 55, pp.109-115

Belge Tipi:

Makale

Yayın Tarihi:

8/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001356118

pISSN:

2980-1915